Insulin Like Growth Factor I – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) – Pipeline Review, H2 2019’, provides in depth analysis on Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular and Central Nervous System under development targeting Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

– The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Boehringer Ingelheim International GmbH

Genervon Biopharmaceuticals LLC

Regulaxis SAS

Stem Cell Medicine Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Overview

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Companies Involved in Therapeutics Development

Boehringer Ingelheim International GmbH

Genervon Biopharmaceuticals LLC

Regulaxis SAS

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drug Profiles

CIGB-845 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-610.27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-7085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit IGF1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

xentuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Discontinued Products

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones

Featured News & Press Releases

Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference

Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm

Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604

May 03, 2016: GM604 to Be Granted “Orphan Drug” Status in Europe

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results

Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS

Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Pipeline by Genervon Biopharmaceuticals LLC, H2 2019

Pipeline by Regulaxis SAS, H2 2019

Pipeline by Stem Cell Medicine Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports